Placebo-controlled trial of cytisine for smoking cessation

New England Journal of Medicine

Volumn 365, Issue 13, 2011, Pages 1193-1200

  West, Robert ^a   Zatonski, Witold ^b   Cedzynska, Magdalena ^b   Lewandowska, Dorota ^b   Pazik, Joanna ^b   Aveyard, Paul ^c   Stapleton, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTISINE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SMOKING; SMOKING CESSATION; SOMNOLENCE; TREATMENT DURATION; XEROSTOMIA;

EID: 80053354033     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1102035     Document Type: Article

References (28)

1. WHO report on the global tobacco epidemic: the MPOWER report. Geneva: World Health Organization, 2008.
2. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38.
3. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519.
4. Framework convention on tobacco control. Geneva: World Health Organization, 2003.
5. Treating tobacco use and dependence: 2008 update. Rockville, MD: Public Health Service, 2008.
6. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2010;12:CD006103.
7. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146.
8. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031.
9. National Institute for Clinical Excellence technology appraisal guidance. No. 38. Nicotine replacement therapy (NRT) and bupropion for smoking cessation. London: National Institute for Clinical Excellence, 2002.
10. Tutka P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin Investig Drugs 2008;17:1473-85.
11. Tutka P, Zatoński W. Cytisine for the treatment of nicotine addiction: from molecule to therapeutic efficacy. Pharmacol Rep 2006;58:777-98.
12. Etter JF, Lukas RJ, Benowitz NL, West R, Dresler CM. Cytisine for smoking cessation: a research agenda. Drug Alcohol Depend 2008;92:3-8.
13. Stoyanov S, Yanachkova M. Treatment of nicotinism with the Bulgarian drug, Tabex. Chimpharm Sofia 1965;2:13.
14. Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind randomised placebocontrolled trial of cytisine for smoking cessation in medium-dependent workers. J Smoking Cessation 2008;3:57-62.
15. Zatonski W, Cedzynska M, Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 2006;15:481-4.
16. Gotti C, Guiducci S, Tedesco V, et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2*receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 2010;30: 5311-25.
17. Rollema H, Shrikhande A, Ward KM, et al. Pre-clinical properties of the alpha- 4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 2010;160:334-45.
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
19. Medical Dictionary for Regulatory Activities (MedDRA) Maintenance and Support Services Organization (MSSO) home page. (http://www.meddramsso.com.)
20. Beck AT, Beamesderfer A. Assessment of depression: the Depression Inventory. Mod Probl Pharmacopsychiatry 1974;7: 151-69.
21. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303.
22. Fagerström K, Furberg H. A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countries. Addiction 2008;103:841-5.
23. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
24. Mottillo S, Filion KB, Belisle P, et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:718-30.
25. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008;197:371-7.
26. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33:289-301.
27. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
28. Shafey O, Eriksen M, Ross H, Mackay J. The tobacco atlas. 3rd ed. Atlanta: American Cancer Society, 2009.